The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

A invenção atual relaciona-se ao uso dos agonists sabidos do receptor central CB1 do cannabinoid para a profilaxia e o tratamento de disorders neurodegenerative, no detalhe para o tratamento do apoplexy cerebral e do trauma craniocerebral.